Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Zacks Research

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research analysts also recently weighed in on COLL. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $57.50.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $36.20 on Monday. The firm has a market cap of $1.17 billion, a PE ratio of 17.75 and a beta of 0.74. Collegium Pharmaceutical has a twelve month low of $29.19 and a twelve month high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The business has a 50-day moving average price of $34.17 and a 200 day moving average price of $39.45.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the business posted $1.49 earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 8.9% on a year-over-year basis. Sell-side analysts predict that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Vident Advisory LLC lifted its holdings in Collegium Pharmaceutical by 1.9% in the 3rd quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after purchasing an additional 281 shares in the last quarter. Quadrant Capital Group LLC raised its position in shares of Collegium Pharmaceutical by 4.2% in the fourth quarter. Quadrant Capital Group LLC now owns 6,996 shares of the specialty pharmaceutical company’s stock valued at $324,000 after buying an additional 282 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 285 shares during the last quarter. Atom Investors LP lifted its stake in shares of Collegium Pharmaceutical by 5.0% in the fourth quarter. Atom Investors LP now owns 6,124 shares of the specialty pharmaceutical company’s stock worth $284,000 after buying an additional 294 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 318 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.